Development and Clinical Evaluation of a Multiplexed Health Surveillance Panel Using Ultra High‐Throughput PRM‐MS in an Inflammatory Bowel Disease Cohort
Angewandte Chemie International Edition · 2025
DOI: 10.1002/anie.202507610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Qin Fu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Mass Spectrometry, Blood Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institutes of Health National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Despite advances in clinical proteomics, translating protein biomarker discoveries into clinical use remains challenging due to the technical complexity of the validation process. Targeted MS‐based proteomic approaches such as parallel reaction monitoring (PRM) offer sensitive and specific assays for biomarker translation. In this study, we developed a multiplex PRM assay using the Stellar mass spectrometry platform to quantify 57 plasma proteins, including 24 FDA‐approved biomarkers. Loading curves (11 points) were performed at 4 sample throughputs (100, 144, 180, and 300 samples per day) using independently optimized and scheduled PRM methods. Following optimization, an inflammatory bowel disease (IBD) cohort of plasma samples (493 IBD, 509 matched controls) was analyzed at a throughput of 180 samples per day. To monitor system performance, the study also included over 1000 additional injections for system suitability tests, low‐, middle‐, and high‐quality controls, washes, and blanks. Using this approach, we observed high quantifiability (linearity, sensitivity, and reproducibility) in the PRM assay and consistent data acquisition across a large cohort. We also validated the candidate IBD markers, C‐reactive protein and orosomucoid protein, identified in a recent discovery experiment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Thermo Fisher Scientific, San Jose, CA, USA.
ORCID-Profile: Christopher I Murray
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institutes of Health National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Disease
Zitieren
APA
Fu, Q., Remes, P. M., Lee, J., Jacob, C., Li, D., Vegesna, M., Raedschelders, K., Haghani, A., Mengesha, E., Debbas, P., Hoedt, E., Joung, S., Cheng, S., Peterman, S., Fert-Bober, J., Melmed, G. Y., McGovern, D. P. B., Murray, C. I., & Van Eyk, J. E. (2025). Development and Clinical Evaluation of a Multiplexed Health Surveillance Panel Using Ultra High‐Throughput PRM‐MS in an Inflammatory Bowel Disease Cohort. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202507610
Vancouver
Fu Q, Remes PM, Lee J, Jacob C, Li D, Vegesna M, et al. Development and Clinical Evaluation of a Multiplexed Health Surveillance Panel Using Ultra High‐Throughput PRM‐MS in an Inflammatory Bowel Disease Cohort. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202507610
BibTeX
@article{Fu2025,
author = {Fu, Qin and Remes, Philip M and Lee, Jihyeon and Jacob, Cristina and Li, Dalin and Vegesna, Manasa and Raedschelders, Koen and Haghani, Ali and Mengesha, Emebet and Debbas, Philip and Hoedt, Esthelle and Joung, Sandy and Cheng, Susan and Peterman, Scott and Fert-Bober, Justyna and Melmed, Gil Y and McGovern, Dermot P B and Murray, Christopher I and Van Eyk, Jennifer E},
title = {Development and Clinical Evaluation of a Multiplexed Health Surveillance Panel Using Ultra High‐Throughput PRM‐MS in an Inflammatory Bowel Disease Cohort},
journal = {Angewandte Chemie International Edition},
year = {2025},
doi = {10.1002/anie.202507610}
}
EUVIMED